University of Texas Texas AM Investment Management Co. Invests $3.97 Million in Pfizer Inc. $PFE

Key Points

• University of Texas Texas A&M Investment Management Co. acquired 165,020 Pfizer shares worth approximately $3.97 million in the second quarter. Institutional investors and hedge funds collectively own 68.36% of Pfizer’s stock.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $28.28; several firms recently lowered their targets.
• Pfizer exceeded quarterly earnings expectations, reporting $0.77 in EPS and $15.03 billion in revenue. The company also declared a quarterly dividend of $0.43 per share, equivalent to a 6.4% annualized yield.

University of Texas Texas AM Investment Management Co. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 165,020 shares of the biopharmaceutical company's stock, valued at approximately $3,974,000.

Other hedge funds have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the second quarter worth $26,000. HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the period. Evolution Wealth Management Inc. grew its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PFE. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. UBS Group reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. HSBC cut shares of Pfizer from a "buy" rating to a "hold" rating and cut their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, JPMorgan Chase & Co. decreased their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $28.28.

Pfizer Stock Performance

NYSE PFE opened at $26.88 on Tuesday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a 50 day moving average of $25.15 and a 200-day moving average of $26.20. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market cap of $153.21 billion, a price-to-earnings ratio of 35.37 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source